Alcon (ALC) said late Wednesday it has acquired a majority stake in Aurion Biotech, a company developing cell therapies to treat eye diseases.
Financial details weren't provided.
Aurion will operate as a separate company to advance its cell therapy asset AURN001 into phase 3 to treat corneal edema secondary to corneal endothelial disease during H2, Alcon said.
Aurion has received breakthrough therapy designation from the US Food and Drug Administration for AURN001, Alcon said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。